Should the novel A2AR antagonists not improve the treatment of Parkinson’s disease vs. the old A2AR antagonists, another hypothesis can be provided for the lack of strong antiparkinsonian actions of the novel A2AR antagonists. Here, ADORA2A is linked to Parkinson disease.